GLYXAMBI Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Glyxambi patents expire, and what generic alternatives are available?
Glyxambi is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are thirteen patents protecting this drug and one Paragraph IV challenge.
This drug has five hundred and fifty-nine patent family members in forty-seven countries.
The generic ingredient in GLYXAMBI is empagliflozin; linagliptin. There are twenty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the empagliflozin; linagliptin profile page.
DrugPatentWatch® Generic Entry Outlook for Glyxambi
Glyxambi was eligible for patent challenges on May 2, 2015.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 14, 2029. This may change due to patent challenges or generic licensing.
There have been eighteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
There are three tentative approvals for the generic drug (empagliflozin; linagliptin), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
Summary for GLYXAMBI
International Patents: | 559 |
US Patents: | 13 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Patent Applications: | 17 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for GLYXAMBI |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for GLYXAMBI |
What excipients (inactive ingredients) are in GLYXAMBI? | GLYXAMBI excipients list |
DailyMed Link: | GLYXAMBI at DailyMed |


DrugPatentWatch® Estimated Generic Entry Opportunity Date for GLYXAMBI
Generic Entry Date for GLYXAMBI*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for GLYXAMBI
Anatomical Therapeutic Chemical (ATC) Classes for GLYXAMBI
Paragraph IV (Patent) Challenges for GLYXAMBI
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
GLYXAMBI | Tablets | empagliflozin; linagliptin | 10 mg/5 mg and 25 mg/5 mg | 206073 | 9 | 2018-08-01 |
US Patents and Regulatory Information for GLYXAMBI
GLYXAMBI is protected by fourteen US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of GLYXAMBI is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting GLYXAMBI
Pharmaceutical composition, methods for treating and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2
DPP IV inhibitor formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Pharmaceutical composition, methods for treating and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Crystalline form of 1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy- )-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA)
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN)
Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
Uses of DPP-IV inhibitors
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Uses of DPP IV inhibitors
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
Pharmaceutical composition, methods for treating and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2
FDA Regulatory Exclusivity protecting GLYXAMBI
ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
Exclusivity Expiration: See Plans and Pricing
INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
Exclusivity Expiration: See Plans and Pricing
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Boehringer Ingelheim | GLYXAMBI | empagliflozin; linagliptin | TABLET;ORAL | 206073-002 | Jan 30, 2015 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Boehringer Ingelheim | GLYXAMBI | empagliflozin; linagliptin | TABLET;ORAL | 206073-002 | Jan 30, 2015 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Boehringer Ingelheim | GLYXAMBI | empagliflozin; linagliptin | TABLET;ORAL | 206073-002 | Jan 30, 2015 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Boehringer Ingelheim | GLYXAMBI | empagliflozin; linagliptin | TABLET;ORAL | 206073-001 | Jan 30, 2015 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for GLYXAMBI
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Boehringer Ingelheim | GLYXAMBI | empagliflozin; linagliptin | TABLET;ORAL | 206073-001 | Jan 30, 2015 | See Plans and Pricing | See Plans and Pricing |
Boehringer Ingelheim | GLYXAMBI | empagliflozin; linagliptin | TABLET;ORAL | 206073-002 | Jan 30, 2015 | See Plans and Pricing | See Plans and Pricing |
Boehringer Ingelheim | GLYXAMBI | empagliflozin; linagliptin | TABLET;ORAL | 206073-001 | Jan 30, 2015 | See Plans and Pricing | See Plans and Pricing |
Boehringer Ingelheim | GLYXAMBI | empagliflozin; linagliptin | TABLET;ORAL | 206073-001 | Jan 30, 2015 | See Plans and Pricing | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for GLYXAMBI
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Boehringer Ingelheim International GmbH | Glyxambi | empagliflozin, linagliptin | EMEA/H/C/003833 Glyxambi, fixed dose combination of empagliflozin and linagliptin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi do not provide adequate glycaemic control;when already being treated with the free combination of empagliflozin and linagliptin. |
Authorised | no | no | no | 2016-11-11 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for GLYXAMBI
When does loss-of-exclusivity occur for GLYXAMBI?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 7970
Estimated Expiration: See Plans and Pricing
Patent: 7657
Estimated Expiration: See Plans and Pricing
Australia
Patent: 08288407
Estimated Expiration: See Plans and Pricing
Brazil
Patent: 0815331
Estimated Expiration: See Plans and Pricing
Canada
Patent: 96558
Estimated Expiration: See Plans and Pricing
Chile
Patent: 08002427
Estimated Expiration: See Plans and Pricing
China
Patent: 1784270
Estimated Expiration: See Plans and Pricing
Patent: 4288166
Estimated Expiration: See Plans and Pricing
Patent: 4353077
Estimated Expiration: See Plans and Pricing
Colombia
Patent: 51239
Estimated Expiration: See Plans and Pricing
Croatia
Patent: 0170022
Estimated Expiration: See Plans and Pricing
Cyprus
Patent: 18308
Estimated Expiration: See Plans and Pricing
Denmark
Patent: 87879
Estimated Expiration: See Plans and Pricing
Ecuador
Patent: 109977
Estimated Expiration: See Plans and Pricing
Eurasian Patent Organization
Patent: 8608
Estimated Expiration: See Plans and Pricing
Patent: 1000321
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 87879
Estimated Expiration: See Plans and Pricing
Patent: 98152
Estimated Expiration: See Plans and Pricing
Patent: 06156
Estimated Expiration: See Plans and Pricing
Patent: 39577
Estimated Expiration: See Plans and Pricing
Hong Kong
Patent: 01721
Estimated Expiration: See Plans and Pricing
Patent: 03351
Estimated Expiration: See Plans and Pricing
Hungary
Patent: 30158
Estimated Expiration: See Plans and Pricing
Patent: 700020
Estimated Expiration: See Plans and Pricing
Israel
Patent: 2886
Estimated Expiration: See Plans and Pricing
Japan
Patent: 95914
Estimated Expiration: See Plans and Pricing
Patent: 10535850
Estimated Expiration: See Plans and Pricing
Lithuania
Patent: 187879
Estimated Expiration: See Plans and Pricing
Patent: 2017014
Estimated Expiration: See Plans and Pricing
Patent: 87879
Estimated Expiration: See Plans and Pricing
Malaysia
Patent: 2037
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 10001696
Estimated Expiration: See Plans and Pricing
Montenegro
Patent: 573
Estimated Expiration: See Plans and Pricing
Morocco
Patent: 612
Estimated Expiration: See Plans and Pricing
Netherlands
Patent: 0872
Estimated Expiration: See Plans and Pricing
New Zealand
Patent: 3242
Estimated Expiration: See Plans and Pricing
Norway
Patent: 17020
Estimated Expiration: See Plans and Pricing
Peru
Patent: 090938
Estimated Expiration: See Plans and Pricing
Poland
Patent: 87879
Estimated Expiration: See Plans and Pricing
Portugal
Patent: 87879
Estimated Expiration: See Plans and Pricing
Serbia
Patent: 205
Estimated Expiration: See Plans and Pricing
Slovenia
Patent: 87879
Estimated Expiration: See Plans and Pricing
South Africa
Patent: 0909105
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 1491554
Estimated Expiration: See Plans and Pricing
Patent: 100049595
Estimated Expiration: See Plans and Pricing
Spain
Patent: 02748
Estimated Expiration: See Plans and Pricing
Taiwan
Patent: 72325
Estimated Expiration: See Plans and Pricing
Patent: 0914030
Estimated Expiration: See Plans and Pricing
Patent: 1436798
Estimated Expiration: See Plans and Pricing
Tunisia
Patent: 10000073
Estimated Expiration: See Plans and Pricing
Ukraine
Patent: 0384
Estimated Expiration: See Plans and Pricing
Uruguay
Patent: 296
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering GLYXAMBI around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 20160128446 | DPP IV 억제제 제형 (DPP IV inhibitor formulations) | See Plans and Pricing |
Spain | 2314743 | See Plans and Pricing | |
Australia | 2003253418 | 8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS | See Plans and Pricing |
Canada | 2649922 | FORMULATIONS DE L'INHIBITEUR DE DPP IV (DPP IV INHIBITOR FORMULATIONS) | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for GLYXAMBI
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1730131 | C01730131/04 | Switzerland | See Plans and Pricing | PRODUCT NAME: EMPAGLIFLOZIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 63227 13.09.2021 |
1532149 | CR 2011 00030 | Denmark | See Plans and Pricing | PRODUCT NAME: LINAGLIPTIN OG SALTE DERAF; NAT. REG. NO/DATE: EU/1/11/707/001-011 20110830; FIRST REG. NO/DATE: EU EU/1/11/707/001-0011 20110830 |
1532149 | PA2011013,C1532149 | Lithuania | See Plans and Pricing | PRODUCT NAME: LINAGLIPTINUM; REGISTRATION NO/DATE: EU/1/11/707/001, 2011-08-24 EU/1/11/707/002, 2011-08-24 EU/1/11/707/003, 2011-08-24 EU/1/11/707/004, 2011-08-24 EU/1/11/707/005, 2011-08-24 EU/1/11/707/006, 2011-08-24 EU/1/11/707/007, 2011-08-24 EU/1/11/707/008, 2011-08-24 EU/1/11/707/00 2011082 |
1730131 | 122014000099 | Germany | See Plans and Pricing | PRODUCT NAME: EMPAGLIFLOZIN UND DESSEN SALZE, INSBESONDERE EMPAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/14/930 20140522 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |